Screener
Gyre Therapeutics, Inc. GYRE Gyre — Fair Value Adjustment Of Warrants
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FairValueAdjustmentOfWarrants.
The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 5:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-340448
| Line item | Three Months Ended June 30, | Six Months Ended June 30, |
|---|---|---|
| Other (loss) income, net: | ||
| Interest income | 941 | 1,797 |
| Other expense, net | (488)) | (301)) |
| Change in fair value of warrant liability | 212 | 2,467 |
| (Loss) Income before income taxes | (1,575)) | 4,265) |
| Benefit (provision) for income taxes | (662) | (1,563)) |
| Net (loss) income | (2,237)) | 2,702) |
| Accretion of Cullgen redeemable convertible preferred stock | (2,642)) | (5,220)) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Gyre Therapeutics, Inc.'s gyre — fair value adjustment of warrants?
- Gyre Therapeutics, Inc. (GYRE) reported gyre — fair value adjustment of warrants of -$132K in Q2 2026.
- How has Gyre Therapeutics, Inc.'s gyre — fair value adjustment of warrants changed year-over-year?
- Gyre Therapeutics, Inc.'s gyre — fair value adjustment of warrants increased by 37.7% year-over-year, from -$212K to -$132K.
- What is the long-term trend for Gyre Therapeutics, Inc.'s gyre — fair value adjustment of warrants?
- Over 2 years (2023 to 2025), Gyre Therapeutics, Inc.'s gyre — fair value adjustment of warrants has grown at a -45.9% compound annual growth rate (CAGR), from $9.26M to -$2.71M.
- What does gyre — fair value adjustment of warrants mean?
- This reflects the periodic change in the estimated market value of outstanding warrants issued by the company. Because these are often classified as financial liabilities, fluctuations in the company's stock price can lead to significant non-cash gains or losses. This metric is essential for understanding volatility in net income that is not related to core business operations.
Ask your AI about Gyre Therapeutics, Inc.'s gyre — fair value adjustment of warrants.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude